Market analysis report forecasts Tadekinig alfa outlook through 2030
A new industry report examines the development status and market projections for AB2 Bio’s investigational therapy, Tadekinig alfa, for the treatment of hemophagocytic lymphohistiocytosis (HLH).
ResearchAndMarkets.com has released an assessment of Tadekinig alfa, an investigational recombinant interleukin-18 binding protein (r-hIL-18BP) being developed by AB2 Bio. The report details the drug's mechanism, focusing on its application for hemophagocytic lymphohistiocytosis (HLH) across the United States, Japan, and five major European nations.
Tadekinig alfa aims to address inflammatory pathology by binding to IL-18, an inflammatory mediator. While earlier research explored the drug's potential for adult-onset Still's disease (AoSD), the report notes that there has been a lack of significant development updates in that area since 2018. Consequently, the provided market forecasts focus primarily on the treatment of HLH.
The report includes an examination of regulatory milestones, R&D progress, patent timelines, and SWOT analysis. By synthesizing industry data, the study provides a 2030 outlook for the asset, reflecting on the competitive landscape and the challenges involved in bringing the therapy to market.